Conference on Retroviruses and Opportunistic Infections (CROI)

Paul Drain, MD, MPH, discusses the results of a study evaluating point-of-care viral load testing and discusses the advantages to implementation.

Following FDA approval of a single-tablet bictegravir, emtricitabine, and tenofovir alafenamide regimen for use in adults with HIV, investigators are exploring the safety and efficacy of the same therapy in children and adolescents aged 6 to 18 years.

Weight gain is often a concern for patients on ART. But what about the metabolic impact of PrEP on HIV-uninfected individuals?

DOLPHIN-2 reports that dolutegravir is well-tolerated and achieves more rapid virological suppression prior to delivery compared to efavirenz when initiated during pregnancy.

Bacterial sexually transmitted infections are still prevalent among men who have sex with men in England, but PrEP and other measures have sharply cut the rate of new HIV diagnoses.

A trial comparing raltegravir with efavirenz for antiretroviral therapy in treatment naïve pregnant women with HIV supports the use of raltegravir, especially for women starting ART later in gestation.

Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, has been fighting HIV/AIDS since the 1980s when the virus was first discovered. Now, thanks to a joint effort by multiple arms of the US Department of Health and Human Services, he’s making headway.

Investigators from England report the longest adult HIV remission observed since the Berlin patient.

Over a 12-month study, there was a 13.9% increase of retention with viral load suppression among participants who received rapid viral load results following point-of-care testing.

The Contagion® editorial staff will be providing exclusive written and video coverage from CROI 2019.